340B drug pricing program reform - Reply

Hagop Kantarjian; Robert Chapman

doi:10.1001/jamaoncol.2015.5403

340B drug pricing program reform - Reply

Hagop Kantarjian, Robert Chapman

Leukemia

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	403-404
Number of pages	2
Journal	JAMA Oncology
Volume	2
Issue number	3
DOIs	https://doi.org/10.1001/jamaoncol.2015.5403
State	Published - Mar 2016

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2015.5403

Cite this

@article{8ce72d37e18141e38afe77cd2b22497d,

title = "340B drug pricing program reform - Reply",

author = "Hagop Kantarjian and Robert Chapman",

year = "2016",

month = mar,

doi = "10.1001/jamaoncol.2015.5403",

language = "English (US)",

volume = "2",

pages = "403--404",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "3",

}

TY - JOUR

T1 - 340B drug pricing program reform - Reply

AU - Kantarjian, Hagop

AU - Chapman, Robert

PY - 2016/3

Y1 - 2016/3

UR - http://www.scopus.com/inward/record.url?scp=85010638176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010638176&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2015.5403

DO - 10.1001/jamaoncol.2015.5403

M3 - Letter

C2 - 26967191

AN - SCOPUS:85010638176

SN - 2374-2437

VL - 2

SP - 403

EP - 404

JO - JAMA Oncology

JF - JAMA Oncology

IS - 3

ER -

340B drug pricing program reform - Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this